Next-generation sequencing (NGS) is emerging as a powerful alternative to traditional viral detection methods for biologics manufacturing. Offering rapid, broad, and sensitive virus identification, NGS addresses the limitations of cell-based assays and animal tests that require long processing times and cover limited virus panels. Regulatory guidelines increasingly endorse NGS for enhanced viral safety assessment, enabling faster, more comprehensive monitoring critical to complex biologic products.